Loading...
Header Logo
Keywords
Last Name
Institution

Navid Sobhani

TitlePostdoc Fellows and Associates
InstitutionBaylor College of Medicine
DepartmentPostDoc
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. D'Angelo A, Sobhani N, Bagby S, Casadei-Gardini A, Roviello G. Cabozantinib as a second-line treatment option in hepatocellular carcinoma. Expert Rev Clin Pharmacol. 2020 May 22; 1-7. PMID: 32394749.
      View in: PubMed
    2. Sobhani N, Corona SP, Roviello G, Bagby S, D'Angelo A, Iezzi G, Generali D. Immune-gene signature: a new tool for patient selection for checkpoint inhibitors? Future Oncol. 2020 May 12. PMID: 32396404.
      View in: PubMed
    3. Roviello G, Sobhani N, Corona SP, D'Angelo A. Corticosteroid switch after progression on abiraterone acetate plus prednisone. Int J Clin Oncol. 2020 Feb; 25(2):240-246. PMID: 31705219.
      View in: PubMed
    4. D'Angelo A, Sobhani N, Roviello G, Bagby S, Bonazza D, Bottin C, Giudici F, Zanconati F, De Manzini N, Guglielmi A, Generali D. Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma. PLoS One. 2019; 14(8):e0219566. PMID: 31381571.
      View in: PubMed
    5. Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N. Avelumab in gastric cancer. Immunotherapy. 2019 06; 11(9):759-768. PMID: 31060469.
      View in: PubMed
    6. Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cells. 2019 04 06; 8(4). PMID: 30959874.
      View in: PubMed
    7. Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World J Clin Oncol. 2018 Dec 20; 9(8):172-179. PMID: 30622925.
      View in: PubMed
    8. Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G. Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. Invest New Drugs. 2018 12; 36(6):1133-1137. PMID: 30083960.
      View in: PubMed
    9. Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. Cells. 2018 Jul 15; 7(7). PMID: 30011957.
      View in: PubMed
    10. Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N. Lenvatinib for the treatment of renal cell carcinoma. Expert Opin Investig Drugs. 2018 05; 27(5):507-512. PMID: 29718721.
      View in: PubMed
    11. Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? World J Clin Oncol. 2018 Apr 10; 9(2):26-32. PMID: 29651384.
      View in: PubMed
    12. Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. J Cell Biochem. 2018 06; 119(6):4287-4292. PMID: 29345357.
      View in: PubMed
    13. Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D. Advances in systemic therapy for malignant mesothelioma: future perspectives. Future Oncol. 2017 Oct; 13(23):2083-2101. PMID: 28984470.
      View in: PubMed
    14. Roviello G, Sobhani N, Generali D. Bevacizumab in small cell lung cancer. Ann Transl Med. 2017 Sep; 5(17):361. PMID: 28936455.
      View in: PubMed
    15. Sobhani N, Generali D, Roviello G. PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. EBioMedicine. 2017 08; 22:18-19. PMID: 28688823.
      View in: PubMed
    16. Sobhani N, Corona SP, Zanconati F, Generali D. Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma. Genes Cancer. 2017 Mar; 8(3-4):495-496. PMID: 28680533.
      View in: PubMed
    Sobhani's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description